Skip to content

Iris Acquisition IRAB Deferred offering costs

Deferred offering costs at other companies

Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$164.72K
Hitachi logo
HitachiHIT
$170.98K
NextNRG, Inc. Common Stock logo
NextNRG, Inc. Common StockNXXT
$18.09K-98.8%
IRA
Iris Acquisition IRAB
$0
Bain Capital Specialty Finance logo
Bain Capital Specialty FinanceBCSF
$3.29M-24.2%
DeFi Development Corp. Common Stock logo
DeFi Development Corp. Common StockDFDV
$3.36M+2,861%

Other financials

Income statement

See full
Operating income-$144.1K
Net income$773.9K

Balance sheet

See full
Cash & equivalents$854.8K
Total debt$84.6K
Total equity-$6.4M
Total assets$170.4M

Cash flow

See full
Operating cash flow-$9.8K

Valuation

See full
Market cap$227.44M+0.2%
Enterprise value$226.67M

Returns & leverage

See full
Debt / equity-0×
Current ratio2.9×

Where this comes from

Reported directly by Iris Acquisition in its filing.

Tagged under the XBRL concept us-gaap:DeferredOfferingCosts.

The official record: Iris Acquisition ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Iris Acquisition 's deferred offering costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Iris Acquisition 's deferred offering costs?
Iris Acquisition (IRAB) reported deferred offering costs of $0 in Q1 2026.
What does deferred offering costs mean?
Costs incurred in the process of preparing for an equity offering that are deferred until the offering is completed. Once the offering occurs, these costs are typically reclassified as a reduction of equity or amortized over time. This metric tracks the total investment made to bring the company to the public market.